Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.56, a high estimate of ...

Names like idarucizumab, levetiracetam and ustekinumab may look like words from Greek or Norse mythology, but they're chosen ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Nurix Therapeutics, Inc.’s NRIX share price has dipped by 11.87%, which has investors questioning if this is right time to buy.

The interplay between aging and cellular senescence reveals insights into chronic inflammation and potential strategies for enhancing healthspan and longevity.

Despite the trial not meeting its primary endpoint, the high dose was well tolerated, with a safety profile comparable to the approved 600 mg dose and no new safety signals observed. These findings ...

Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intravenous (IV) infusion to the ...